908 Devices Inc. Stock Price, News & Analysis

908 Devices (NASDAQ:MASS) announced a successful collaboration with Transcenta, enhancing biopharmaceutical workflows in Hangzhou, China. Their ZipChip® device accelerated the measurement of monoclonal antibodies (mAbs), achieving results in under 10 minutes—100 times faster than traditional methods. Transcenta also adopted the REBEL® device for near real-time amino acid analysis, supporting continuous cell culture. This partnership highlights the efficacy of 908 Devices' tools in bioprocess improvements and emphasizes their growing presence in the Asia Pacific region.

908 Devices Inc. (Nasdaq: MASS) announced it will release its financial results for Q2 2021 on August 4, 2021, before market open. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET, available via live webcast on the company’s website. The session will be archived for replay within 24 hours. 908 Devices specializes in mass spectrometry devices that serve critical applications in life sciences and forensics, showcasing its commitment to making laboratory tools more accessible.

908 Devices (NASDAQ:MASS) has announced partnerships with Sartorius and Securecell to enhance its REBEL™ platform for bioprocess labs. These integrations allow users to harness advanced data analytics and improve operational excellence in process development. Key features include seamless data flow from REBEL into Sartorius’ SIMCA for better data visualization and trend analysis, as well as enhanced monitoring capabilities with Securecell’s Lucullus for Critical Process Parameters. This collaboration aims to empower customers with actionable bioanalytics information and drive high yields in bioprocessing.

908 Devices (NASDAQ: MASS) has appointed Dr. Marcia Eisenberg, the chief scientific officer of Labcorp Diagnostics, to its Board of Directors. Dr. Eisenberg brings over 30 years of experience in biotechnology, molecular genetics, and forensic DNA testing, having developed many clinical assays. Kevin Hrusovsky, chairman of 908 Devices, lauded her proven track record and relevant expertise as a vital asset. This appointment follows the recent addition of two board members earlier this year, indicating ongoing efforts to strengthen its leadership team.

908 Devices (Nasdaq: MASS), a leader in handheld mass spectrometry, will virtually participate in the William Blair 41st Annual Growth Stock Conference. The management team's fireside chat is scheduled for June 3rd at 11:20 a.m. PT / 2:20 p.m. ET. Interested individuals can access the live webcast through the company's Investors section. 908 Devices aims to make mass spectrometry accessible for critical applications in various fields including life sciences and forensics.

908 Devices reported a 39% increase in Q1 2021 revenue, totaling $5.5 million compared to $4.0 million in Q1 2020. Product and service revenue surged over 100%, driven by strong sales of MX908 and Rebel units. The installed base grew to 1,427 devices, with 66 new placements in the quarter. However, the company reported a net loss of $6.1 million, up from $3.0 million in the prior year. Operating expenses also rose to $8.7 million. The full year 2021 revenue guidance is set between $38 million and $40 million, a growth rate of 41% to 49%.

908 Devices (NASDAQ:MASS) announced significant updates to its MX908 handheld mass spec device. The new Aero module enables real-time detection of aerosolized chemical threats, enhancing response protocols for first responders. The device now identifies a broader range of drug substances, addressing key concerns highlighted in the National Drug Threat Assessment. Additionally, the newly launched Bluetooth capability allows for efficient data transfer to Android devices, improving workflow and safety. These advancements come after a recent $25 million deal with the U.S. Army.

908 Devices (NASDAQ: MASS) announced the addition of six new members to its Scientific Advisory Board, enhancing its leadership in bioprocess development and biotherapeutics. The new members, including experts from academia and industry, will provide guidance on the company's bioprocessing and bioanalytics platform. This strategic move aims to support the expansion of the Rebel and ZipChip ecosystems, positioning 908 Devices to advance its technology roadmap and support users in biotherapeutic development and production.

Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) have announced a collaboration to develop a comprehensive protein characterization solution. This integration will combine Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip device. The partnership aims to streamline workflow for scientists, enhancing drug development efficiency via in-depth analysis of biotherapeutics. The combination of these technologies is expected to deliver faster commercialization, leveraging high-resolution separation techniques and mass spectrometry capabilities.